BioArctic AB is a research-based biopharmaceutical company focusing on disease-modifying treatments and diagnostics for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, and ALS... Show more
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where BRCTF advanced for three days, in of 18 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for BRCTF just turned positive on August 05, 2025. Looking at past instances where BRCTF's MACD turned positive, the stock continued to rise in of 19 cases over the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 71 cases where BRCTF Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 21 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 19 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
BRCTF broke above its upper Bollinger Band on August 28, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. BRCTF’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (14.205) is normal, around the industry mean (19.994). P/E Ratio (27.082) is within average values for comparable stocks, (51.700). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.073). Dividend Yield (0.000) settles around the average of (0.044) among similar stocks. P/S Ratio (15.576) is also within normal values, averaging (325.279).
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BRCTF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Industry Biotechnology
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
EXHAX | 26.81 | 0.11 | +0.41% |
Manning & Napier Pro-Blend Max Term S | |||
CWMAX | 65.85 | 0.15 | +0.23% |
American Funds Washington Mutual 529A | |||
HMDCX | 26.63 | 0.05 | +0.19% |
Hartford MidCap C | |||
POIIX | 15.58 | N/A | N/A |
Polen International Growth Institutional | |||
NEFSX | 47.17 | -0.13 | -0.27% |
Natixis US Equity Opportunities A |
A.I.dvisor indicates that over the last year, BRCTF has been loosely correlated with CNSP. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if BRCTF jumps, then CNSP could also see price increases.
Ticker / NAME | Correlation To BRCTF | 1D Price Change % | ||
---|---|---|---|---|
BRCTF | 100% | N/A | ||
CNSP - BRCTF | 37% Loosely correlated | +0.65% | ||
CGTX - BRCTF | 28% Poorly correlated | +0.77% | ||
VTVT - BRCTF | 28% Poorly correlated | -1.24% | ||
RENB - BRCTF | 25% Poorly correlated | -3.23% | ||
ENTX - BRCTF | 22% Poorly correlated | -4.63% | ||
More |